DRAFT RESOLUTION 1.
2
COUNCIL
: World Health Organization (WHO)
SPONSORS : Brazil, Germany, Japan, Myanmar, United States of America, Viet Nam
The World Health Organization,
Alarmed that tuberculosis has infected 8.6 million people all across the globe
annually and is considered as a disease with second highest mortality rate after
HIV/AIDS;
Deeply concerned that access to proper and standardized treatments and health
services remain inaccessible to more than 3 million people across the globe;
Recognizing the need for joint programme between WHO and diverse UN body,
limited but not limited to UN Women, UNICEF, WFP, UNAIDS, UNDP, UNHRC and
UNHCR to significantly expand and strengthen its work on global, regional and
national level in combating tuberculosis;
Recognizing the many factors contributing to the spread and transmission of
tuberculosis, including but not limited to weakened immune system due to
malnutrition and other diseases such as HIV/AIDS;
Recognizing the different needs and problems faced by vulnerable groups, including
women, children, persons with HIV/AIDS, internally displaced people and refugees,
and persons living below the poverty line in receiving accessible tuberculosis
treatments and other related health services;
Recalling the General Assemblys resolution A/RES/58/179 on Access to medication
in the context of pandemics such as HIV/AIDS, tuberculosis, and malaria;
Recalling its resolution WHA44.8 on Tuberculosis control programme, resolution
WHA53.1 on Stop Tuberculosis Initiative, resolution WHA58.14 on Sustainable
financing for tuberculosis prevention and control, resolution WHA60.19 on
Tuberculosis control: progress and long-term planning, and resolution WHA62.15
on Prevention and control of multidrug-resistant tuberculosis and extensively drugresistant tuberculosis;
Taking into account the Commission on Narcotic Drugs resolution 53/4 on
Promoting adequate availability of internationally controlled licit drugs for medical
and scientific purposes while preventing their diversion and abuse and resolution
54/6 on Promoting adequate availability of internationally controlled narcotic drugs
and psychotropic substances for medical and scientific purposes while preventing
their diversion and abuse;
Having considered the WHA62/15 report on The prevention and control of
multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis;
Urges all Member States:
1) To achieve greater accessibility of health services and information related to
the promotion, prevention, treatment, care and recovery of tuberculosis by
means of:
a. Establishing more accessible testing centers to increase the availability
of standardized early diagnosis in order to reduce mortality rate
caused by tuberculosis;
b. Increasing the number and distribution of health care service centers,
including clinics hospitals, with a priority for vulnerable groups
including but not limited to women, children, persons with HIV/AIDS,
persons living below national and/or global poverty line, and persons
living in inaccessible areas;
c. Making available sufficiently trained and motivated staffs in order to
enable diagnosis treatment and care on tuberculosis including multidrug resistance (MDRTB) and extensively drug resistance tuberculosis
(XDR-TB) by means of skill improvement training aimed at both general
and specialized health workers through cooperation with nongovernmental organizations (NGO) and inter-governmental
partnership;
d. Promoting multi-sector discussion regarding the global crisis posed by
the tuberculosis pandemic through the dissemination of important
materials on efforts to fight the epidemic
e. Encouraging the incorporation of education on tuberculosis in health
education classes on primary, secondary, and tertiary levels of
education as well as the establishment of national-level campaigns
against tuberculosis and discrimination to eradicate wrong stigma and
misconceptions;
f. Introducing the decentralized production of generic, cheap, and
effective drugs for tuberculosis to increase the accessibility of
tuberculosis drugs for all and to lessen the dependency of high
tuberculosis burden countries on patented drugs;
g. Introducing more efficient distribution system to increase access of TB
drugs for at-risk vulnerable and/or inaccessible groups by, but not
limited to, the means of minimizing and standardizing the shape of the
drugs to increase its quantity in distribution;
Emphasizes the importance of comprehensive tuberculosis prevention programmes
as an essential element in tailoring national, regional, and international actions and
policies to tailor it to the local profile and the TB pandemic;
Endorses financial and technical assistance for the advancement of tools,
technology, and medicine to combat tuberculosis by means of:
1. Increasing financial contributions made to date to the Global Fund to Fight
AIDS, Tuberculosis and Malaria;
2. Empowering the work of Global Health Innovative Technology Fund (GHIT
Fund) for the research and development of innovative tools and drugs to
combat tuberculosis, including MDR-TB, XBR-TB and HIV/AIDS-related TB, as
well as the development of accessible generic drugs and vaccines to improve
the currently available tuberculosis vaccine (BCG) or to develop a new and
more effective vaccine altogether, especially seeing that the currently
available vaccine is not effective for children;
3. Strengthening the work of Stop TB Partnership Working Group and Global
Alliance for TB Drug Development;
Strongly urges Members States of World Health Organization to deploy nationallevel laws, policies, and investments in order to eradicate the prevalence of
tuberculosis in their states with focuses on research and development (R&D) as well
as the production of accessible medicines and vaccines;
Strongly urges Member States to incorporate care services during and in the
aftermath of the tuberculosis treatment, including but not limited to the monitoring
of nutrition intake and sanitation;
Urges Member States to give a focus on the different needs and problems faced by
women and children in accessing treatments for and information regarding
tuberculosis by means of:
1. Encouraging the development of children-friendly drugs and vaccines as the
current tuberculosis drugs require three to four different drugs for at least
eighteen months of treatments with commendation of even more drugs and
at least six months of injection that may have severe side effects for children;
2. Encouraging the development of pregnant women-friendly drugs which have
no possible severe side effects that may affect the condition of the pregnant
women and their fetus;
3. Integrating maternal, children, and women health services, HIV care, and
tuberculosis care into a seamless package of national healthcare system;
Strengthens inter-United Nations bodies cooperation to eradicate tuberculosis,
including cooperation with, but not limited to, the following UN bodies:
1. UN-WOMEN for grassroots education and campaigns regarding the rights of
women for access to information, education, and medication with a focus on
pregnant women, single mothers living below poverty line, and childrearing
women;
2. UNICEF for the promotion of the incorporation of health education on national
education system with an emphasize of education on awareness for
tuberculosis;
3. World Food Programme (WFP) to strengthen its assistance for governments to
integrate food and nutrition into health programmes and to build broad safety
nets that protect livelihoods of persons with tuberculosis;
4. UNAIDS to strengthen its assistance for governments and regional bodies to
promote anti-discrimination campaigns for persons with HIV/AIDS and TB as
well as to promote joint-research to ensure accessible medicine and
treatment for persons with HIV/AIDS and TB;
Strengthens support for treatment and care for tuberculosis during humanitarian
emergencies and/or conflicts by means of:
- Short term: Encourage cooperation with national, regional, and international
partners and stakeholders to establish accessible and safe supportive health
care services to address tuberculosis and aid in its recovery during and
immediately following the emergencies
- Long term: Establishment of sustainable and widely accessible communitybased health system after the emergency
Expands the MDR-TB management to cover MDR-TB sufferers by the means of:
1. Strengthening the framework of the Greenlight Committee Initiative
partnered with STOP TB to raise funds for establishing policies and principles
from national- and government-supported agencies, regional and
international organizations, non-governmental organizations, universities,
research institutions, and other sources;
2. Ensuring transparency of distribution and management of health services and
medicines by encouraging government-supported national monitoring and
transparency assessment along with assessments sponsored by World Health
Organization and non-governmental organizations;
Supports the eradication MDR-TB and XDR-TB altogether in the near future by the
means of:
1. Standardizing the Greenlight Committee Initiative (GCI) to support the
expansion of the MDR-TB treatments and care, to promote technical
assistance to countries in the implementation and application of the
standardized treatments, to monitor and evaluate GLC-approved programmes
in ensuring their adherence to WHO and United Nations guidelines, and assist
the development of policies on national and global level to control MDR-TB;
2. Calling upon Member States to offer their financial assistance for Global
Health Innovative Technology Fund (GHIT Fund) for the development of
cheaper and more effective drugs for MDR-TB and XDR-TB;
Encourages global and private-public partnership with an aim to eradicate
tuberculosis in the near future by the means of:
1. PUBLIC-PRIVATE PARTNERSHIP
a. Encouraging partnership between government and civil societies to
establish community-based, grassroots health care services and
information systems, with a focus of civil societies for vulnerable
groups, including people suffering from HIV/AIDS;
b. Encouraging partnership between government and non-governmental
organizations to assist in the monitoring and assessment of the
implementation of existing national and global policies, the distribution
of drugs to unreachable areas, and knowledge transfer for local doctors
and health service workers;
c. Encouraging partnership between government and multinational
corporations with corporate social responsibility (CSR) programs,
especially those in pharmaceutical and hospital industry, to assist in
knowledge transfer and research and development of innovative tools
and drugs to combat TB;
d. Encouraging partnership between government and mediaincluding
news outlets and social mediasto promote anti-discrimination
campaign aimed at eliminating misconceptions and wrong stigma of
the society in regards to tuberculosis;
2. GLOBAL PARTNERSHIP
a. Encouraging bilateral agreements and the development of national
laws to employ strict screening policies for immigrants upon their
arrival to resolve cross-border issues;
b. Encouraging a universal standard for tuberculosis treatments and
prevention programmes;
c. Implementing effective monitoring, evaluation, and impact
measurement system for existing initiatives, global or otherwise,
including The Global Fund, DOTS and DOTS+, as well as the Stop TB
Strategy, to ensure political commitment, effective drug supply and
management system, as well as standardized treatment for
tuberculosis patients;